EcoDrugPlus

Checkpoint Kinase 1

Ensembl ID : ENSVPAG00000011641
Gene Symbol: CHEK1
1 Cross references
177 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSVPAG00000002823
Gene Symbol: CHEK2
1 Cross references
205 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSVPAG00000003622
Gene Symbol: CCKAR
1 Cross references
200 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSVPAG00000009472
Gene Symbol: CHRM2
1 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSVPAG00000007167
Gene Symbol: CHRM5
1 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSVPAG00000008262
Gene Symbol: CHRNA3
1 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSVPAG00000008265
Gene Symbol: CHRNB4
1 Cross references
198 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSVPAG00000005276
Gene Symbol: F2R
1 Cross references
327 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSVPAG00000012339
Gene Symbol: F11
1 Cross references
216 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSVPAG00000012586
Gene Symbol: CCDC6
1 Cross references
219 Possible Orthologues:

Complement C1s

Ensembl ID : ENSVPAG00000007118
Gene Symbol: C1S
1 Cross references
199 Possible Orthologues:

Complement C5

Ensembl ID : ENSVPAG00000009197
Gene Symbol: C5
1 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).